Current commercial sources of hyaluronic acid (HA) are derived from either rooster combs or various attenuated strains of Streptococcus. Due to the risk of animal-derived contamination of the final product, the use of HA produced by rooster comb extraction is decreasing in the industry.
Streptococci are inherently pathogenic to human beings due to their secretion of toxins and resulting hemolytic properties. In addition, both production methods employ large volumes of organic solvents in different steps of the process, which can lead to impurities in the final HA ingredient.
What is Bacillus-derived hyaluronic acid?
Novozymes has developed the next-generation HA, the world’s first and only recombinant source of HA based on the fermentation of Bacillus subtilis, in a Q7 validated cGMP process.
Working with raw materials that are already Q7 compliant can help medical device and pharmaceutical drug manufacturers reduce testing time, save on manufacturing costs and take products to market faster.
Faster dissolving time reduces processing time
- Up to 5 x faster dissolving time at production scale
- Proven to reduce production time by up to 30-50%
Superior heat stability ensures a more consistent final product
- Ability to withstand autoclaving in solution
- Improved molecular weight and viscosity retention
Safety and purity for reduced risk of contamination
- No animal-derived materials or organic solvents
- Very low levels of endotoxins and proteins
Consistency delivered each time, every time
- Targeted molecular weights with narrow polydispersity
- High batch-to-batch consistency in production at large-scale
Unique and customized solutions for desired viscosity
- Dedicated R&D support team with significant HA expertise
- Proprietary crosslinking technology helps achieve desired viscosity
cGMP, Q7 validated process at large-scale
- Security of supply from a sustainable company
- Supply from a Q7 validated facility.